

Title of paper:	Payment by Results 2013/2014 Drug and Device Exclusions Proposed commissioning intentions for new interventions starting in 2013/14
Author:	Clare Johns, Senior Pharmacy Technician for Pharmaceutical Commissioning, Surrey & Sussex Commissioning Support Unit
Exec Lead:	
Date:	19 th July 2013
Locality:	All
Meeting:	Governing Body
Agenda item:	
For:	To appraise the Governing Body of the proposed arrangements for transfer of commissioning intentions for payment by results excluded (PbRe) drugs and devices from NHS Surrey to NHS Surrey Downs CCG
<p>Brief summary</p> <p>The tariff payment system is nationally calculated averages. It is expected that against the tariff, providers will incur a deficit or surplus in the course of providing a care event. A number of high cost drugs, devices, procedures and products have been excluded from the scope of the national tariff of payment by results (PbR) for 2013/2014. Following the reorganisation of the NHS these drugs will either be:</p> <ul style="list-style-type: none"> - commissioned by the specialised commissioning group (SCG) which are part of the NHS England OR - commissioned by the Clinical Commissioning Groups (CCGs) <p>This document provides a statement of Surrey Downs CCG commissioning intentions and arrangements for managing these drug exclusions which are the responsibility of the CCGs for 2013/14. PbR drug exclusions are linked to British National Formulary (BNF) categories where possible. Any new drugs added to these BNF categories within the financial year will be treated as drug exclusions. Activity will be monitored for the use of these drugs in line with NICE or locally commissioned criteria. PbR drug exclusions will only be funded at the Provider's acquisition cost, with no additional costs added.</p>	

Quality and patient safety issues:

Financial issues:

Patient and Public Engagement

Workforce issues:

Statutory compliance:

It is a requirement that the commissioning intentions are authorised for use by the governing body to be applied in contracts with the local acute Trusts

Conflicts of interest:

Risk and assurance: Please describe the relationship between this issue and any risks on the risk register or relevant Assurance Framework requirements.

Accompanying papers (please list):

Payment by Results 2013/2014 Drug and Device Exclusions